Setmelanotide Lowers Weight, Hunger in Bardet-Biedl Syndrome, Phase 3 Trial Shows
One year of treatment with setmelanotide was safe and resulted in a significant drop in body weight and hunger in Bardet-Biedl syndrome (BBS) patients, ages 12 years and older, with moderate to severe obesity, according to top-line data from a Phase 3 clinical trial. “We are pleased with…